

03-04-02

A

BAKER BOTTS LLP

30 ROCKEFELLER AUSTIN
PLAZA BAKU
44TH FLOOR DALLAS
NEW YORK, NEW YORK HOUSTON
10112-0228 LONDON
212.705.5000 MOSCOW
FAX 212.705.5020 **NEW YORK**
WASHINGTON

**UTILITY PATENT
APPLICATION
TRANSMITTAL**

*(Only for nonprovisional
applications under 37 CFR 1.53(b))*

PATENT

Attorney Docket No. A33474-PCT-USA-A-068528.0103First Named Inventor Maria de Lourdes HiguchiExpress Mail Label No. EU206385812USCustomer No.: 21003Total Pages: 72

March 1, 2002

BY EXPRESS MAIL - Label No. EU206385812US**Box: Patent Application**

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

Enclosed herewith for filing is a patent application of Higuchi et al. entitled "PREVENTION
AND TREATMENT OF MYCOPLASMA-ASSOCIATED DISEASES" which includes:

☒ Specification 63 Total Pages

☒ Background of the Invention; Summary of the Invention;
Description of the Figures; Detailed Description of
the Invention; Examples; and Tables 44 pages

☒ Claims 2 pages

☒ Abstract 1 page

☒ Drawings Figs. 1-2 16 sheets

☒ formal

☐ informal

☐ Combined Declaration and Power of Attorney pages

☐ Newly executed (original or copy)

☐ Copy from a prior application filed

☒ If a continuing application, check appropriate box:

☒ Continuation ☐ Divisional ☐ Continuation-In-Part
of PCT/BR01/00083 filed July 3, 2001 in English."

☒ Amend the specification by inserting, before the first line, the following sentence:

"This is a ☒ continuation ☐ divisional ☐ continuation-in-part
of PCT/BR01/00083 filed July 3, 2001, which claims priority to Brazilian patent applications
PI 0002989-0 filed July 3, 2000 and PI filed July 3, 2001."

☒ The entire disclosures of the prior applications are considered as being part of the disclosure of the accompanying application and are hereby incorporated by reference therein.

☐ An Assignment of the invention to

☐ is attached. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.

☐ will follow.

☐ has been filed

☒ Small Entity Statement(s)

☐ is/are attached.

☐ filed in prior application. Status still proper and desired.

☒ will follow.

☐ Information Disclosure Statement

__ pages

☐ PTO Form 1449

__ pages

☐ Copies of 9 citations are enclosed.

☐ Copies of the remaining IDS Citations are not required.

Also accompanying this patent application are:

☐ Application Data Sheet

☐ CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix)

☐ Non-Publication Request

☒ Nucleotide and/or Amino Acid Sequence Submission

☒ Letter Requesting Transfer of Computer Readable Sequence Listing 2

☒ Return Receipt Postcard

☒ Other Preliminary Amendment 2

☒ The filing fee has been calculated as shown below:

FOR	(Col. 1) No. Filed	(Col. 2) No. Extra	Small Entity Rate	Small Entity Fee	OR	Other Than A Small Entity Rate	Other Than A Small Entity Fee
Basic Fee				\$370.00			\$740.00
Total Claims	15	-20 = 0	x 9 =	\$0.00		x 18 =	\$0.00
Ind. Claims	2	-3 = 0	x 42 =	\$0.00		x 84 =	\$0.00
Multiple Dependent Claim			+ 140 =			+ 28 = 0	\$0.00
			Total	\$370.00			\$

* If the difference in Col. 1 is less than zero, enter "0" in Col. 2.

Fee:


☒ Enclosed☒ Basic filing fee \$370.00☐ Recording Assignment \$0.00
[\$40.00; 37 CFR 1.21(h)]☒ Total Fees Enclosed \$370.00☐ A check in the amount of \$ to cover filing fee is enclosed.☒ Please charge our Deposit Account No. 02.4377 in the amount of \$370.00. Two copies of this sheet are enclosed.

Priority:

☒ Priority is claimed of application Serial No. PCT/BR01/00083 filed July 3, 2001 and English applications Serial No. PI 0002989-0 filed July 3, 2000 and PI filed July 3, 2001.☒ Certified Copy(ies)☐ has/have been filed in the parent application S/N _____.☐ is/are attached.☒ will follow.☒ The Commissioner is hereby authorized to charge payment of any additional filing fees required under 37 CFR 1.16, 1.17, and 1.21(h) associated with this communication or credit any overpayment to Deposit Account No. 02-4377. Two copies of this sheet are enclosed.☒ The Commissioner is hereby authorized to charge payment of any additional fees associated with this communication or credit any overpayment to Deposit Account No. 02-4377. Two copies of this sheet are enclosed.☒ The Commissioner is conditionally authorized to charge payment of any fees associated with this application or credit any overpayment to Deposit Account No. 02-4377. Two copies of this sheet are enclosed.

Respectfully submitted,

BAKER BOTTS L.L.P.



Lisa Kole

Patent Office Reg. No. 35,225

Anthony Giaccio

Patent Office Reg. No. 39,684

Attorneys for Applicants

(212) 408-2500

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Higuchi *et al.*
Serial No. : Not Yet Assigned Examiner : Not Yet Assigned
Filed : March 1, 2002 Group Art Unit: Not Yet Assigned
For : PREVENTION AND TREATMENT OF MYCOPLASMA-
ASSOCIATED DISEASES

**SUBMISSION OF SEQUENCE LISTING
AND DECLARATION**

BY EXPRESS MAIL – Label No. EU206385812US

March 1, 2002

U.S. Patent and Trademark Office
Box Patent Application
Arlington, Virginia 22202

Sir:

Submitted herein are paper and computer-readable copies of the Sequence Listing for the accompanying above-captioned application.

I hereby state that the content of the paper and computer readable copies of the Sequence Listing submitted in accordance with 37 C.F.R. § 1.821(c) and (e), respectively, are the same.


I hereby state that the content of the paper and computer readable copies of the Sequence Listing, submitted herewith in accordance with 37 C.F.R. § 1.82(f), does not include new matter.

It is believed that no fee is required in connection with this communication.

However, if any fee is required in connection with this communication, the Commissioner is hereby authorized to charge payment of any such fee to Deposit Account No. 02-4377. Two copies of this communication are enclosed.

Respectfully submitted,

BAKER BOTTS L.L.P.


Lisa B. Kole M.D., Ph.D.
Patent Office Reg. No. 35,225

Anthony Giaccio
Patent Office Reg. No. 39,684

Attorneys for Applicants
(212) 408-2500

Enclosures